For laboratory and research use only — not for human consumption. All content is educational.
Use case

Peptides for memory research

Memory is not a single endpoint. Encoding, consolidation, and recall draw on different molecular systems, and the peptides relevant to memory research target those systems at different points. This hub collects the catalogued peptides studied for memory-related endpoints, explains where each one acts in the memory pipeline, and notes the mechanistic overlap and divergence that determines which one a research design needs.

The endpoint

What 'memory research' actually means

Memory in the laboratory is operationalised through several distinct paradigms. In rodent research, Morris water maze and novel object recognition probe spatial and recognition memory; passive avoidance and conditioned fear probe associative memory; radial arm maze probes working memory. In human research, paired-associate learning, digit span, and delayed-recall tasks probe declarative memory; specific procedural tasks probe non-declarative systems. A peptide that improves one of these does not automatically improve the others.

The peptides on this page act on memory through three principal mechanisms: BDNF/NGF induction (Semax, Noopept, Cerebrolysin), synaptogenesis (Dihexa), and multi-pathway neurotrophic mimicry (Cerebrolysin). The clinical and preclinical evidence bases differ substantially in maturity. Read the per-peptide profiles for the specific evidence; this page is the navigational hub.

The candidates

Peptides relevant to memory research

Cognitive Enhancement

Semax

A synthetic heptapeptide analogue of ACTH(4-10) developed in Russia for cognitive enhancement, neuroprotection, and stroke recovery research.

Neuroprotection

Cerebrolysin

A complex mixture of low-molecular-weight peptides and free amino acids derived from porcine brain tissue, studied extensively in cognitive decline and post-stroke recovery research.

Neurogenesis

Dihexa

An orally active hexapeptide derivative of angiotensin IV, characterised in academic research as among the most potent known pro-cognitive compounds in animal models.

Cognitive Enhancement

Noopept (Peptide Note)

A small proline-containing dipeptide derivative — technically a peptidomimetic — developed in Russia as an orally active cognitive enhancer with structural lineage to piracetam.

Cognitive Enhancement

N-Acetyl Semax Amidate

A chemically protected analogue of Semax with N-terminal acetylation and C-terminal amidation, conferring substantially extended half-life and improved potency in research.

Picking between them

How researchers choose

By mechanism

If the research question is about BDNF-mediated plasticity specifically, Semax or Noopept are the cleanest tools. If the question is about new-synapse formation, Dihexa's c-Met agonism is the focused choice. Cerebrolysin is the multi-pathway comparator when the question is "what happens with broad neurotrophic support".

By route practicality

Intranasal is the standard for Semax and the acetylated analogue; oral for Noopept (via the active metabolite cycloprolylglycine); parenteral infusion for Cerebrolysin; oral or subcutaneous for Dihexa in animal work. The route constraint often decides which peptide a particular research protocol can practically accommodate.

By evidence depth

Cerebrolysin has the deepest randomised clinical-trial record in memory-related indications. Semax has the deepest single-peptide clinical evidence. Noopept has both Russian clinical data and substantial preclinical mechanism work. Dihexa has striking preclinical data but no human trials.

By model system

Aged-animal models with reduced baseline BDNF show stronger Semax/Noopept effects than young-healthy models. Ischaemia and post-stroke models show Cerebrolysin's effects most clearly. Synaptogenesis assays in hippocampal slice preparations are the standard Dihexa endpoint.

FAQ

Common questions

It depends on whether you weight clinical or preclinical data. Cerebrolysin has the largest body of randomised clinical trials in memory-related indications (vascular dementia, post-stroke recovery). Semax has the strongest published clinical evidence among single-peptide compounds, primarily in Russian post-stroke trials. Dihexa has the strongest preclinical synaptogenic data in aged-animal models but no human trials. Noopept has both Russian clinical data and a large body of preclinical mechanistic work.
BDNF inducers hubSynaptogenic hubBDNF research summary